title: [From marker expression to individual therapy of patients with bladder cancer].
abstract: Urothelial carcinoma of the bladder is a tumor entity with a heterogenous clinical course. At one end of the spectrum, patients are treated for low-grade carcinomas, which are likely to reccur but show low rates of tumor progression. At the other end, patients suffer from noninvasive or early invasive high-grade carcinomas. In these cases, risk-adapted treatment decisions are more complicated. The following article gives an overview of research activities on bladder cancer with the aim to individualize treatment of patients with bladder cancer.
authors: Klinik und Poliklinik für Urologie, Kinderurologie und urologische Onkologie, Universitätsklinikum, Essen, Deutschland. frankvomDorp@web.de
authors: F
authors: F
authors: Vom Dorp
authors: C
authors: C
authors: Börgermann
authors: T
authors: T
authors: Jäger
authors: M
authors: M
authors: Becker
authors: K W
authors: KW
authors: Schmid
authors: H
authors: H
authors: Rübben
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D002295:Carcinoma, Transitional Cell / Q000473:pathology* / Q000628:therapy; D003131:Combined Modality Therapy; D018450:Disease Progression; D006801:Humans; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis; D012106:Research; D046888:Tissue Array Analysis; D001743:Urinary Bladder / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000473:pathology* / Q000628:therapy
chemical_list: D014408:Biomarkers, Tumor